Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In response the novel coronavirus emergency, the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) has activated its Clinical Characterisation Protocol (CCP) for emerging infections in England and Scotland.

Coronavirus © Alissa Eckert, MS; Dan Higgins, MAM

The Clinical Characterisation Protocol (CCP) was prepared for just such an emergency. It provides an ethically approved framework for enrolling patients to a clinical study which will offer new insights into this emerging global threat.

The CCP facilitates the collection of standardised clinical data and samples on patients hospitalised with suspected or confirmed infection with novel coronavirus. This will inform the outbreak response and patient care, not just in the UK but internationally. With novel coronavirus patients now identified in the UK, the UK health research community is well-prepared to advance our understanding of this disease.

The Chief Investigator for the UK CCP is Professor Calum Semple at the University of Liverpool. The development of the CCP was led by Dr Kenneth Baillie at the University of Edinburgh. The CCP study is sponsored by the University of Oxford and ISARIC’s Global Support Centre is hosted by the University of Oxford. ISARIC’s Members have developed the CCP over a number of years.

The CCP is supported by the National Institute for Health Research (NIHR) and is now open to enrolment in NHS Trusts, including the network of high-containment clinical facilities where patients with novel coronavirus will be admitted in the early stages of the disease in the UK.

ISARIC is a global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases. ISARIC’s mission is to generate and disseminate clinical research evidence for outbreak-prone infectious diseases, whenever and wherever they occur.

ISARIC is funded by the Wellcome Trust, the UK Department for International Development, and the Bill & Melinda Gates Foundation.

Similar stories

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.